CG Oncology Reports Executive & Board Changes, Compensation Details
Ticker: CGON · Form: 8-K · Filed: Feb 16, 2024 · CIK: 1991792
| Field | Detail |
|---|---|
| Company | Cg Oncology, Inc. (CGON) |
| Form Type | 8-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $9,919, $2,217, $760, $317 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
TL;DR
**CG Oncology just shook up its leadership and compensation, signaling potential strategic shifts ahead!**
AI Summary
CG Oncology, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 15, 2024. The filing indicates changes in the company's leadership, specifically regarding the departure or election of directors and the appointment of certain officers, along with details on their compensatory arrangements. This suggests a restructuring or significant personnel changes within the company's executive and board ranks.
Why It Matters
Changes in leadership and executive compensation can signal strategic shifts, impact investor confidence, and affect the company's future direction and performance.
Risk Assessment
Risk Level: medium — Changes in key personnel can introduce uncertainty regarding future strategy and operational stability, warranting a medium risk assessment.
Key Numbers
- 001-41925 — Commission File Number (Identifies the company's filing with the SEC)
- 37-1611499 — IRS Employer Identification No. (Identifies the company for tax purposes)
- 949-409-3700 — Business Phone (Primary contact number for the company)
Key Players & Entities
- CG Oncology, Inc. (company) — Registrant
- February 15, 2024 (date) — Date of earliest event reported
- February 16, 2024 (date) — Filed as of date
- Delaware (company) — State of Incorporation
- 001-41925 (dollar_amount) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 16, 2024.
What is the primary business address of CG Oncology, Inc.?
The primary business address of CG Oncology, Inc. is 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618.
What specific items are covered in this 8-K filing?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
What is the state of incorporation for CG Oncology, Inc.?
CG Oncology, Inc. is incorporated in Delaware.
Filing Stats: 938 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-02-16 16:21:07
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CGON The Nasdaq Stock Mar
- $9,919 — d in early 2023. (3) Amounts reflect $9,919 and $2,217 in 401(k) matching contribut
- $2,217 — 2023. (3) Amounts reflect $9,919 and $2,217 in 401(k) matching contributions for Mr
- $760 — Bellete and Dr. Kasturi, respectively, $760, $317 and $253 in company-paid premiums
- $317 — te and Dr. Kasturi, respectively, $760, $317 and $253 in company-paid premiums for l
- $253 — . Kasturi, respectively, $760, $317 and $253 in company-paid premiums for long-term
- $666 — Bellete and Dr. Kasturi, respectively, $666, $278 and $222 in company-paid premiums
- $278 — te and Dr. Kasturi, respectively, $666, $278 and $222 in company-paid premiums for l
- $222 — . Kasturi, respectively, $666, $278 and $222 in company-paid premiums for life insur
- $1,548 — lete and Dr. Kasturi, respectively, and $1,548 related to a company-paid holiday-relat
- $357,908 — i. Amount for Mr. Bellete also reflects $357,908 for his services as a consultant to the
Filing Documents
- d773011d8k.htm (8-K) — 41KB
- 0001193125-24-038506.txt ( ) — 165KB
- cgon-20240215.xsd (EX-101.SCH) — 3KB
- cgon-20240215_lab.xml (EX-101.LAB) — 18KB
- cgon-20240215_pre.xml (EX-101.PRE) — 11KB
- d773011d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CG Oncology, Inc. Date: February 16, 2024 By: /s/ Arthur Kuan Name: Arthur Kuan Title: Chairman and Chief Executive Officer